• <tr id="yyy80"></tr>
  • <sup id="yyy80"></sup>
  • <tfoot id="yyy80"><noscript id="yyy80"></noscript></tfoot>
  • 99热精品在线国产_美女午夜性视频免费_国产精品国产高清国产av_av欧美777_自拍偷自拍亚洲精品老妇_亚洲熟女精品中文字幕_www日本黄色视频网_国产精品野战在线观看 ?

    Efficacy and safety of Revlimid combined with Rituximab in the treatment of follicular lymphoma: A meta-analysis

    2023-12-06 07:54:42WuYoujiaoLiuLinBIXiaomanZHENGShaojiang
    Journal of Hainan Medical College 2023年15期
    關鍵詞:濾泡淋巴瘤單抗

    Wu You-jiao, Liu Lin, BI Xiao-man,2?, ZHENG Shao-jiang?

    1.Tumor Institute, the First Affiliated Hospital of Hainan Medical University, Haikou 570102, China

    2.College of Biomedical Information and Engineering, Hainan Medical University, Haikou 571199, China

    Keywords:

    ABSTRACT Objective: To evaluate the clinical efficacy and safety of lenalidomide combined with rituximab for treating follicular lymphoma.Methods: We searched PubMed, Web of Science,Cochrane Library, Embase, China Medical Biological Service system (CBM), VIP database(VIP), Wan fang database (Wan Fang Data), China Knowledge Network (CNKI), and ClinicTrails.gov for literature related to lenalidomide combined with rituximab for treating follicular lymphoma (until June 23, 2022).The literature that met the requirements were screened out according to the established criteria, and the data were analyzed by RevMan5.4 and Stata14.0 to conduct a meta-analysis.Results: Eight studies involving 865 patients with follicular lymphoma were included.The results of the meta-analysis showed that the objective remission rate (RR = 1.43, 95% CI: 1.26–1.61) and complete remission rate (RR = 1.67, 95%CI: 1.27–2.21) of lenalidomide combined with rituximab for treating follicular lymphoma were

    1.Introduction

    Follicular lymphoma (FL) is the most common inert lymphoma and the second most common non-Hodgkin’s lymphoma (NHL).FL is characterized by diffuse lymph node enlargement, bone marrow involvement, and splenomegaly, and has a significant biological and clinical heterogeneity[1].The progress of FL is slow and the survival time is long.Moreover, few patients in the early stage of disease can be cured by radiotherapy[2].Because the advent of the anti-CD20 monoclonal antibody rituximab, the survival of patients with recurrent or refractory FL has been improved, and the survival time has been extended to 20 years[3, 4].However, some patients have a risk of recurrence and transformation into invasive lymphoma, with poor prognosis[5].Increasing evidence has shown that the tumor microenvironment (TME) participates in the disease progression and drug resistance of B-cell malignant tumors by promoting tumor growth and helping malignant cells to escape immune recognition.Immunomodulatory drugs (such as lenalidomide) not only have direct anti-tumor activity but also target various cells in the TME,including T cells, NK cells, and stromal cells by interfering with tumor signal transduction and activating the anti-tumor immune response[6, 7].Lenalidomide has achieved good clinical results as a single drug for treating tumors, and combined therapy can produce a lasting response to FL.Although most patients are initially treated with lenalidomide combined with rituximab, its efficacy and safety need to be further verified.

    Here, we conducted a meta-analysis to evaluate the efficacy and safety of lenalidomide combined with rituximab for treating FL,to explore the relevant research at home and abroad, summarize the relevant conclusions, and provide strong data support for evidencebased medicine to guide clinical decision-making.

    2.Materials and methods

    2.1 Selection criteria

    2.1.1 Inclusion criteria

    Research types: randomized controlled trials, non-randomized controlled trials, and single-arm clinical trials published at home and abroad on lenalidomide combined with rituximab for treating FL, limited to Chinese and English, irrespective of the blind method and published status; subjects: patients with FL diagnosed by pathological examination, regardless of sex, race, age, disease stage,and previous treatment; intervention: lenalidomide combined with rituximab used to treat FL in the experimental group, and rituximab alone was used to treat FL in the control group; outcome indicators:the objective and complete remission rates were employed as effectiveness indicators, and adverse reactions were used as safety indicators.

    2.1.2 Exclusion criteria

    Duplicate studies, reviews, case reports, and studies in which the number of patients in the study group was < 10; animal experiments and basic research; literature in which the research content or outcome index was inconsistent with the inclusion criteria; the research design was not rigorous, or the treatment or intervention measures were not related to the experiment; and the data were incorrect.

    2.2 Literature retrieval

    Web of Science, Embase, PubMed, The Cochrane Library, China Medical Student Material Service system, China Knowledge Network, VIP database, Wan fang database, and ClinicTrails.gov were searched for relevant literature.The publication time of the literature was from the inception of the database until June 23, 2022.The search words were a combination of subject and free words.The Chinese keywords included “來那度胺,” “利妥昔單抗,” and “濾泡性淋巴瘤,” while the English keywords included “Revlimid,”“IMiD3 Cpd,” “CC5013,” “CC5013,” “CC-5013,” “Revlimid,”“Rituximab,” “CD20 Antibody, Rituximab,” “Rituximab CD20 Antibody,” “Mabthera,” “Lymphoma, Follicular,” and “Follicular Lymphomas,” among others.

    2.3 Data extraction and methodological quality evaluation

    2.3.1 Data extraction

    All of the relevant retrieved literature were imported into the EndNote software, the software management program was used to integrate the literature, and the literature related to this research topic was screened out.Two evaluators independently screened the titles and abstracts of all studies acquired during the literature retrieval and analyzed whether they met the selection criteria.In cases where this information could not be accurately judged, the full text was first obtained to determine whether the study should be included.If this could not be established from the full text review, a consensus was reached through discussion or based on the judgment of a third researcher.

    2.3.2 Quality assessment

    The Cochrane bias quality risk assessment tool was used to evaluate the quality of RCT literature, including whether it accorded with random sequence distribution, whether it accorded with the concealment of distribution mode, whether it blinded the experimenter or researcher, whether it lacked the outcome index,whether it reported the experimental results, and whether other biases existed.The above statistical data were evaluated at three levels: “high-risk bias,” “l(fā)ow-risk bias,” and “uncertain risk bias.”For literature on non-RCTs and single-arm experimental studies,MINORS evaluation terms were selected for quality evaluation, as shown in our previous research methods[8]: A total of 12 evaluation indicators were used, of which the first eight applied to the study without a control group, each with a score of 0~2, in which 0 indicated “unreported,” 1 indicated “reported but insufficient information,” and 2 indicated “reported and provides sufficient information,” and thus, full marks for the first eight indicators would total 16 points.According to the MINORS evaluation table, only studies with a total score ≥ 13 were included in the meta-analysis.

    2.4 Statistical analysis

    RevMan5.4 and Stata15 software were used to analyze the data.Q-test was employed to evaluate the heterogeneity of the study, and P values < 0.05 were considered statistically different.The fixed effect model whenI250%, indicating good homogeneity between the studies; in contrast, if the heterogeneity of each study was large,we first analyzed the causes of the heterogeneity, before making reasonable analysis and judgment according to the specific situation.In cases where the cause of heterogeneity was easily obtained,the random effect model was employed to analyze and make a descriptive explanation; in contrast, when the data heterogeneity was too large to make a reasonable explanation, the cause of heterogeneity was investigated through sensitivity or subgroup analysis.The relative risk ratio (RR) and its 95% confidence interval(CI) were used for the analysis of the objective response rate (ORR)and complete response rate (CRR) in RCT, and the risk difference(RD) and its 95% CI were used for the analysis of the objective remission rate, complete remission rate, and all adverse reactions in the non-RCTs.Adverse reactions were defined as any adverse events that occurred during treatment.The funnel chart was used to investigate the presence of publication bias in the results.

    3.Results

    3.1 Literature screening process and results

    Through a preliminary search of subject words, a total of 413 articles were retrieved.Based on the screening criteria (Fig.1), eight articles[9-16] were included in this study, including seven English articles[9-15] and one Chinese article[16].

    3.2 Basic characteristics of the included literature and bias risk assessment

    Among the eight included studies, the research data were more complete.After summarizing the basic characteristics of the studies,we found no significant difference in age, tumor stage, course of treatment, and treatment strategy between the experimental and control groups.Five articles[9, 10, 12, 14, 16] were single-arm studies,and three[11, 13, 15] were RCTs (the control group participated in the statistical study of single-arm trials).The trial groups of eight studies were treated with lenalidomide combined with rituximab, and the control groups of three studies were treated with rituximab with or without placebo.The basic characteristics of the control group included in the study are detailed in Table 1.According to the items of the Cochrane bias quality risk assessment tool (see Fig.2 for details).

    Tab 1 Characteristics of the included studies

    Fig 2 Summary of risk of bias

    3.3 Meta-analysis results

    3.3.1 Objective remission rate

    3.3.1.1 Meta-analysis with a single-arm test method

    Seven articles[10-16] met the criteria of the meta-analysis, involving 865 patients, including 296 patients with ORR.The fixed effect model was used for the meta-analysis of the single-arm dichotomous data.The results showed that I2= 0 < 50%, P = 0.76 > 0.05.The analysis showed that the combined effect test of RD =[0.87, 95% CI= [0.79, 0.96],Z= 20.17 was statistically significant (P< 0.00001).The results showed that lenalidomide combined with rituximab was effective in treating FL, with an objective remission rate of 87%.

    3.3.1.2 Meta-analysis according to the experimental method of the control group

    A total of 543 patients were included in the three articles[11, 13, 15]that met the requirements of analysis, including the treatment group(n= 270) and control group (n= 273).Analysis of the fixed effect model showed that I2= 0 < 50%, P = 0.79 > 0.05, RR = 1.43, and 95% CI: [1.26, 1.61], while the combined effect test showed Z = 5.76P< 0.00001, which was statistically significant (see Fig.4).These results suggest that the objective remission effect of lenalidomide combined with rituximab for treating FL is better than that of the control group.

    Fig 3 Meta-analysis on the ORR of Revlimid plus Rituximab for treating FL

    Fig 4 Meta-analysis on the ORR of Revlimid plus Rituximab for treating FL in RCT

    3.3.2 Complete remission rate

    3.3.2.1 Meta-analysis with a single-arm test method

    Seven articles[10-16] met the criteria for analysis, involving 865 patients, including 296 patients with CR.The random effect model was used to conduct a meta-analysis of the single-arm dichotomous data, withI2= 81% > 50%.The large heterogeneity was found to be caused by the inclusion of more single-arm studies.The analysis obtained RD = 0.58, 95% CI = [0.50,0.67], while the combined effect test showedZ= 13.48,P< 0.00001; the result was statistically significant (Fig.5).Lenalidomide combined with rituximab may be effective for treating FL, with a complete remission rate of 58%.However, more high-quality randomized trials need to be included.

    3.3.2.2 Meta-analysis according to the experimental method of the control group

    The information on 543 patients was included in three articles[11,13, 15], including 270 cases in the treatment group and 273 cases in the control group.The fixed effect model analysis showed that I2=0 < 50%,P= 0.79 > 0.05.TheRR= 1.67 and 95%CI= [1.27,2.21]were obtained by the analysis, and the combined effect test showed Z = 3.62, which was statistically significant (Fig.6).The objective remission effect of lenalidomide combined with rituximab for treating FL was better than that of rituximab alone and better than that of the control group.

    Fig 5 Meta-analysis on the CR of Revlimid plus Rituximab for treating FL

    Fig 6 Meta-analysis on the CR of Revlimid plus Rituximab for treating FL in RCT

    3.3.3 Main adverse reactions

    Eight articles[9-16] selected in this study reported the main adverse reactions from ten aspects, including neutropenia, lymphopenia,thrombocytopenia, anemia, fatigue, diarrhea, nausea and vomiting,rash, infection, and thrombosis.The results of the subgroup analysis of different evaluation criteria are shown in Fig.7.

    Statistical analysis of the data in the reported neutropenia literature[9, 11, 12, 14, 16] showed thatP= 0.06 < 0.1,I2= 54%> 50%, with moderate heterogeneity.Using the random effect model, the effect doseRD= 0.33, 95%CI= [0.18, 0.49], while the Q test showedP< 0.0001, which was statistically significant.Approximately 33% of patients have adverse reactions to neutropenia during the treatment of FL with lenalidomide combined with rituximab.

    Based on the statistical analysis of the data in the literature on lymphopenia[11, 12, 15, 16], the results showed thatP< 0.01,I2=78% > 50%, with large heterogeneity.Analysis using the random effect model showed RD = 0.21, 95% CI: = [0.06 and 0.48], and no statistical significance in the Q test (P= 0.13 > 0.05).

    Statistical analysis reported the data of thrombocytopenia[9, 11, 12,15, 16] in the literature.The results showed that P > 0.01, I2= 47% <50%, with low heterogeneity, while the fixed effect model showed the effect doseRD= 0.15, 95%CI= [0.02, 0.32], passed the Q test(P = 0.09 > 0.05), and had no statistical significance.

    Based on the statistical analysis of the data in the literature reporting anemia[9, 12, 15], the results showed thatP< 0.01,I2= 59 >50%, which was evaluated as moderate heterogeneity; the random effect model showed that the effect wasRD= 0.17, 95%CI: = [0.05,0.38], with no statistical significance according to the Q test (P>0.05).

    According to the statistical analysis of the data of the literature on fatigue, the results showed thatP< 0.0001,I2= 82% > 50%,indicating high heterogeneity.Therefore, a random effect model was adopted, the results of which demonstrated RD = 0.37, 95%CI= [0.12, 0.62], andP= 0.004 < 0.05.Moreover, approximately 37% of patients developed symptoms of fatigue during treatment with lenalidomide combined with rituximab for FL.However, the heterogeneity was high, possibly due to the number of articles included in more single-arm studies; therefore, it is necessary to include more high-quality randomized experimental studies in the future.

    Statistical analysis of the data related to diarrhea[9, 12, 15] showed that P > 0.01, I2= 0% < 50%, with low heterogeneity.The results of the fixed effect model demonstrated that the effect amountRD= 0.29, 95%CI: = [0.16, 0.43], andP< 0.0001.Moreover,approximately 29% of patients developed diarrhea during treatment with lenalidomide combined with rituximab for FL.

    Statistical analysis of the data related to nausea or vomiting in the literature[9, 12, 15] showed that P > 0.01, I2= 0% < 50%, and low heterogeneity.The results of the fixed effect model demonstrated that the effect amountRD= 0.17, 95%CI= [0.04, 0.31], andP<0.05.Lenalidomide combined with rituximab for FL was associated with a 17% chance of causing nausea or vomiting.

    Statistical analysis of the data of the literature reporting rash events[9, 11, 12, 14-16] showed that P = 0.35 > 0.01, I2= 10% < 50%,with low heterogeneity.The results of the fixed effect model showed thatRD= 0.20, 95%CI= [0.09, 0.31],P< 0.05.Furthermore,approximately 20% of the patients developed a rash during treatment with FL and lenalidomide combined with rituximab.

    Based on the data of selected literature related to infection[11-13,15,16], the fixed effect model showed that P = 0.37 > 0.01, I2= 6%< 50%, low heterogeneity,RD= 0.11, 95%CI= [0.01, 0.23],P=0.08 > 0.05, and no statistical significance.The data related to thrombus from selected literature[13,15,16] were analyzed by the fixed effect model, which demonstratedP= 0.89 >0.01,I2= 0% < 50%, low heterogeneity,RD= 0.04, 95%CI= [0.13,0.20],P= 0.67 > 0.05, and no statistical significance.

    Fig 7 Meta-analysis on adverse events of Revlimid plus rituximab for treating FL

    3.4 Bias analysis

    The objective remission rate (Fig.8A) and complete remission rate (Fig.8B) were analyzed by Stata14.0, and the figures were symmetrical.We conducted a symmetry test of the above two pictures (Figs.8C–D), P = 0.051 > 0.05, P = 0.946 > 0.05, and the results showed that the funnel diagram was basically symmetrical,suggesting no obvious publication bias in the literature of this study.

    4.Discussion

    Lenalidomide, as a targeted immunomodulatory drug combined with rituximab, has become a new treatment option for recurrent FL, including patients who show inadequate responses to rituximab alone, and those who wish to avoid cytotoxic chemotherapy[17].In the phase III AUGMENT trial, lenalidomide + rituximab significantly prolonged PFS in patients with recurrent or refractory inert NHL compared to placebo + rituximab, and the PFS benefit was prominent in patients with FL.Lenalidomide + rituximab also showed significant activity in the phase III MAGNIFY trials in patients with recurrent or refractory inert NHL, including those with disease that was refractory to rituximab [18,19].Although grade 3 or 4 neutropenia occurred more frequently in the lenalidomide +rituximab group than in the placebo + rituximab group, it could be controlled by adjusting the dose.However, there remains a lack of high-level clinical evidence for its therapeutic efficacy and safety.

    Accordingly, the efficacy and safety of lenalidomide combined with rituximab for treating FL were evaluated by a meta-analysis.Combined with single-arm and control group experiments, compared to rituximab alone for treating FL, the objective remission rate and complete remission rate of lenalidomide combined with rituximab for treating FL were significantly improved.During treatment, the risk of adverse reactions, such as neutropenia, diarrhea, nausea and vomiting, and rash, was relatively high, but the overall proportion is at a low level, so it is necessary to make corresponding treatment for the related adverse reactions.In view of these adverse reactions,the existing medical level can be improved or inhibited to varying degrees by drugs or other means.Additionally, due to the high heterogeneity of adverse reaction indices, such as lymphocytopenia and fatigue, more controlled trials need to be included for further exploration.

    The purpose of this study was to demonstrate the clinical effect of lenalidomide in treating FL.Previous studies have shown heterogeneity in the treatment regimen and duration of patients with different subtypes of B-cell lymphoma.Here, clinical studies on FL were screened strictly according to the inclusion criteria to avoid the risk of greater heterogeneity after analysis with other types of NHLs,including diffuse large B-cell lymphoma, mantle cell lymphoma,and primary central nervous system lymphoma.Additionally, the drugs involved in this experiment were relatively consistent, which confirms the actual clinical efficacy after the control variables.

    This study had some limitations.First, some of the included studies were single-arm, which may lead to a certain degree of deviation in the results.Second, the small sample size may lead to a certain risk of bias, which requires the inclusion of, large-sample, multicenter clinical randomized controlled trials in the future.Third,although the intervention measures in the literature study were set as lenalidomide combined with rituximab for the treatment of FL, differences in the dosage and cycle among the studies may have a certain impact on the results of the meta-analysis.Fourth,although the relevant data were collected comprehensively, due to the different outcome indicators in different studies, some outcome indicators could not be integrated and analyzed.Fifth, as only Chinese and English literature were included, the literature was not comprehensive and the inclusion of ethnic groups was limited.Sixth, a few of them have been included in the literature for a long time, but the disease is in the process of continuous development and variation, so there may be some limitations in the significance of clinical guidance.Finally, publication bias inevitably occurred in the literature, because studies with statistically significant results were relatively easy to publish, while those with negative results were not.Therefore, more well-designed prospective large-sample, multicenter randomized controlled trials are needed to re-analyze and evaluate the effectiveness and safety of this study.

    Currently, lenalidomide combined with rituximab or rituximab alone is the standard first-line or follow-up treatment option for advanced FL, while other treatment options (e.g., PI3K inhibitors,tazemestostat, and CAR-T cell therapy) continue to evolve[2].Studies have shown that several small molecular inhibitors involved in the proliferation of PI3 kinase and BTK have anti-FL activity[20,21].Additionally, the EZH2 inhibitor tazemestostat was approved by the FDA for FL after previous second-line treatment[22].Notably,chimeric antigen receptor T cells (CART) or bispecific antibody constructors have a unique therapeutic mechanism in FL[23, 24].In view of these potential non-cross-reaction mechanisms, the design and optimization of combination strategies are expected to improve the outcome of FL, and may even achieve a cure.Therefore, at present, there is still an urgent need for personalized methods, trial endpoints for quality of life measurement, guidance on available schemes, and information on drug sequencing[25].The research and development of new drugs and the continuous discovery of the pathogenic mechanism of FL are expected to improve the prognosis and quality of life of patients with FL.

    In this study, compared to the CD20 antibody rituximab alone,lenalidomide combined with rituximab showed greater efficacy in alleviating FL.Although the combination may bring some side effects, such as neutropenia, nausea, vomiting, and rash, most can be relieved by providing symptomatic treatment or adjusting the drug dose to reduce the occurrence of symptoms.

    猜你喜歡
    濾泡淋巴瘤單抗
    HIV相關淋巴瘤診治進展
    傳染病信息(2022年3期)2022-07-15 08:24:12
    超聲診斷甲狀腺濾泡型腫瘤的研究進展
    司庫奇尤單抗注射液
    認識兒童淋巴瘤
    高頻甲狀腺超聲對濾泡性腫瘤的診斷價值
    曲妥珠單抗治療后進展的轉移性乳腺癌繼續(xù)曲妥珠單抗治療的療效及安全性分析
    癌癥進展(2016年12期)2016-03-20 13:16:10
    使用抗CD41單抗制備ITP小鼠的研究
    鼻咽部淋巴瘤的MRI表現(xiàn)
    磁共振成像(2015年5期)2015-12-23 08:52:50
    甲狀腺乳頭狀癌濾泡亞型聲像圖及臨床病理特征分析
    原發(fā)性甲狀腺淋巴瘤1例報道
    99久久无色码亚洲精品果冻| 好看av亚洲va欧美ⅴa在| 国产视频一区二区在线看| 美女午夜性视频免费| 亚洲国产欧美人成| 麻豆成人午夜福利视频| 看免费av毛片| 亚洲av日韩精品久久久久久密| 亚洲精华国产精华精| 制服诱惑二区| 精品久久久久久久久久久久久| 好看av亚洲va欧美ⅴa在| 亚洲全国av大片| 国产精品一区二区三区四区久久| 麻豆av在线久日| 性欧美人与动物交配| 国产成人精品久久二区二区免费| 午夜视频精品福利| 美女高潮喷水抽搐中文字幕| 久久午夜亚洲精品久久| 高潮久久久久久久久久久不卡| 又紧又爽又黄一区二区| 国产91精品成人一区二区三区| 人成视频在线观看免费观看| 亚洲国产中文字幕在线视频| 国产精品99久久99久久久不卡| 在线视频色国产色| 18禁美女被吸乳视频| e午夜精品久久久久久久| 脱女人内裤的视频| 亚洲 欧美 日韩 在线 免费| 国产精品,欧美在线| 亚洲五月天丁香| 亚洲avbb在线观看| 又紧又爽又黄一区二区| 99热只有精品国产| 亚洲欧美日韩高清专用| 国产1区2区3区精品| 色哟哟哟哟哟哟| 免费电影在线观看免费观看| 嫁个100分男人电影在线观看| 特大巨黑吊av在线直播| 国语自产精品视频在线第100页| 搡老岳熟女国产| 91av网站免费观看| 久久草成人影院| 久久精品亚洲精品国产色婷小说| 国产精品久久久av美女十八| 久久中文字幕人妻熟女| 91麻豆av在线| 亚洲欧美精品综合一区二区三区| 黄片小视频在线播放| 又大又爽又粗| 黑人欧美特级aaaaaa片| 人妻夜夜爽99麻豆av| 亚洲熟妇中文字幕五十中出| 亚洲欧美激情综合另类| 国产精品乱码一区二三区的特点| 亚洲自拍偷在线| 国产精品精品国产色婷婷| 非洲黑人性xxxx精品又粗又长| 精品久久久久久久人妻蜜臀av| 99久久久亚洲精品蜜臀av| 长腿黑丝高跟| 三级毛片av免费| 看黄色毛片网站| 男人舔奶头视频| 90打野战视频偷拍视频| 国产97色在线日韩免费| 日韩国内少妇激情av| 国产成人系列免费观看| 麻豆av在线久日| 中文在线观看免费www的网站 | www.www免费av| 正在播放国产对白刺激| 精品一区二区三区视频在线观看免费| 变态另类丝袜制服| 国产日本99.免费观看| 欧美乱码精品一区二区三区| 美女午夜性视频免费| 亚洲黑人精品在线| 中文在线观看免费www的网站 | 欧美色欧美亚洲另类二区| 国产亚洲精品av在线| 亚洲欧美日韩无卡精品| 两个人视频免费观看高清| 久久草成人影院| 色老头精品视频在线观看| 一a级毛片在线观看| 欧美在线一区亚洲| 久久国产精品人妻蜜桃| 亚洲专区中文字幕在线| 免费看美女性在线毛片视频| 色av中文字幕| 全区人妻精品视频| 亚洲av美国av| 久久香蕉激情| 国产精品亚洲美女久久久| 一级a爱片免费观看的视频| 51午夜福利影视在线观看| 欧美一级毛片孕妇| 女同久久另类99精品国产91| 亚洲av成人av| 又爽又黄无遮挡网站| 亚洲欧美日韩东京热| 久久精品夜夜夜夜夜久久蜜豆 | 亚洲一区二区三区不卡视频| 国产在线观看jvid| 母亲3免费完整高清在线观看| 日本三级黄在线观看| 黑人巨大精品欧美一区二区mp4| 国产精品一及| bbb黄色大片| 在线观看舔阴道视频| 国产成人系列免费观看| 十八禁人妻一区二区| 国产成人av激情在线播放| 老司机靠b影院| 欧美日韩中文字幕国产精品一区二区三区| 国产日本99.免费观看| 日韩国内少妇激情av| 日本 av在线| 久久久久九九精品影院| 国产成人精品久久二区二区免费| 亚洲国产看品久久| 欧美成人一区二区免费高清观看 | 午夜两性在线视频| 国产精品日韩av在线免费观看| 老司机午夜十八禁免费视频| 精品福利观看| 九色成人免费人妻av| 免费在线观看黄色视频的| 日韩欧美在线乱码| 亚洲自拍偷在线| 久久久久久久精品吃奶| e午夜精品久久久久久久| 久久 成人 亚洲| 亚洲av五月六月丁香网| 99re在线观看精品视频| 一本久久中文字幕| 日韩欧美在线乱码| 极品教师在线免费播放| 免费看日本二区| 亚洲色图av天堂| 亚洲欧美日韩无卡精品| 一边摸一边抽搐一进一小说| 成人一区二区视频在线观看| 国产av在哪里看| 国产成人精品久久二区二区91| 日韩欧美在线二视频| 黑人巨大精品欧美一区二区mp4| 美女高潮喷水抽搐中文字幕| 亚洲一卡2卡3卡4卡5卡精品中文| 黑人操中国人逼视频| 亚洲国产精品sss在线观看| 免费搜索国产男女视频| 日日爽夜夜爽网站| 成人三级黄色视频| 黄片大片在线免费观看| 亚洲 欧美一区二区三区| 男人舔女人的私密视频| 两个人视频免费观看高清| 国产精品永久免费网站| 欧美一区二区精品小视频在线| av有码第一页| 可以免费在线观看a视频的电影网站| 亚洲最大成人中文| 亚洲美女视频黄频| 日本一区二区免费在线视频| 亚洲色图av天堂| 亚洲男人天堂网一区| 国产真实乱freesex| 亚洲午夜理论影院| 国产精品久久久久久精品电影| 欧美乱妇无乱码| 亚洲精品av麻豆狂野| av中文乱码字幕在线| 国产黄色小视频在线观看| 精品久久久久久成人av| 少妇粗大呻吟视频| 午夜福利在线观看吧| 91老司机精品| www.自偷自拍.com| 色播亚洲综合网| 最新美女视频免费是黄的| 每晚都被弄得嗷嗷叫到高潮| 51午夜福利影视在线观看| 国内久久婷婷六月综合欲色啪| 熟女电影av网| 久久中文字幕一级| 国产久久久一区二区三区| 老司机靠b影院| 在线观看美女被高潮喷水网站 | 午夜福利高清视频| 啪啪无遮挡十八禁网站| 免费在线观看日本一区| 99国产极品粉嫩在线观看| 日韩av在线大香蕉| 看片在线看免费视频| 在线观看一区二区三区| 欧美人与性动交α欧美精品济南到| 成人精品一区二区免费| av欧美777| 欧美色视频一区免费| 91在线观看av| 国产私拍福利视频在线观看| 1024手机看黄色片| 欧美 亚洲 国产 日韩一| 国产成年人精品一区二区| 成年免费大片在线观看| 亚洲成人免费电影在线观看| 天天添夜夜摸| 中文在线观看免费www的网站 | 久久久国产成人精品二区| 亚洲午夜精品一区,二区,三区| 深夜精品福利| 可以免费在线观看a视频的电影网站| 一级黄色大片毛片| 90打野战视频偷拍视频| 亚洲欧洲精品一区二区精品久久久| 天天躁夜夜躁狠狠躁躁| 免费看十八禁软件| 少妇熟女aⅴ在线视频| 国产高清视频在线观看网站| 欧美一级毛片孕妇| 午夜福利高清视频| 免费看十八禁软件| 一本大道久久a久久精品| 宅男免费午夜| 老司机午夜福利在线观看视频| 久久久久久免费高清国产稀缺| 久久久久久大精品| 丰满人妻熟妇乱又伦精品不卡| 三级国产精品欧美在线观看 | 午夜精品在线福利| 久久久久免费精品人妻一区二区| 黄片小视频在线播放| 三级毛片av免费| 黄色成人免费大全| 精品国产乱码久久久久久男人| 国产精品一区二区免费欧美| 国产一区在线观看成人免费| 欧美成狂野欧美在线观看| 91在线观看av| 美女黄网站色视频| 久久久久国产一级毛片高清牌| 老司机靠b影院| 一级片免费观看大全| 亚洲精品av麻豆狂野| 中文字幕人成人乱码亚洲影| 久99久视频精品免费| 老熟妇乱子伦视频在线观看| 听说在线观看完整版免费高清| 99热这里只有精品一区 | 欧美在线黄色| 成人av在线播放网站| 757午夜福利合集在线观看| 十八禁网站免费在线| 色综合欧美亚洲国产小说| 日本黄大片高清| 久久久久久久精品吃奶| 91九色精品人成在线观看| 在线永久观看黄色视频| 久久精品国产99精品国产亚洲性色| 欧美三级亚洲精品| 99久久无色码亚洲精品果冻| 757午夜福利合集在线观看| 国产三级黄色录像| 日韩欧美国产在线观看| 搡老岳熟女国产| 国产熟女午夜一区二区三区| 三级男女做爰猛烈吃奶摸视频| 俄罗斯特黄特色一大片| 看免费av毛片| 国产主播在线观看一区二区| 国产区一区二久久| 少妇粗大呻吟视频| 99riav亚洲国产免费| 欧美绝顶高潮抽搐喷水| 亚洲狠狠婷婷综合久久图片| 日日夜夜操网爽| 亚洲美女视频黄频| 久久草成人影院| 午夜视频精品福利| 午夜福利视频1000在线观看| www日本在线高清视频| 久久香蕉国产精品| 中文字幕最新亚洲高清| 午夜福利欧美成人| 亚洲免费av在线视频| 不卡一级毛片| 99riav亚洲国产免费| 亚洲国产精品合色在线| 亚洲性夜色夜夜综合| 久久人妻av系列| 无遮挡黄片免费观看| 99re在线观看精品视频| 亚洲免费av在线视频| 精品一区二区三区视频在线观看免费| 亚洲五月天丁香| 无限看片的www在线观看| 久久久久久久午夜电影| 亚洲av成人精品一区久久| 亚洲片人在线观看| 两人在一起打扑克的视频| 亚洲一区二区三区色噜噜| 性色av乱码一区二区三区2| 国产99久久九九免费精品| 丰满的人妻完整版| 国产激情久久老熟女| 成人国产一区最新在线观看| 给我免费播放毛片高清在线观看| 国产精品98久久久久久宅男小说| 露出奶头的视频| 国产成人av激情在线播放| 少妇被粗大的猛进出69影院| www.精华液| 天天躁夜夜躁狠狠躁躁| 一本一本综合久久| 老司机靠b影院| 又大又爽又粗| 黑人巨大精品欧美一区二区mp4| 亚洲国产精品成人综合色| 国产亚洲精品综合一区在线观看 | 中文字幕久久专区| 男女床上黄色一级片免费看| 淫妇啪啪啪对白视频| 在线观看一区二区三区| 老司机午夜福利在线观看视频| 国产高清视频在线播放一区| 午夜精品久久久久久毛片777| 久久精品91蜜桃| 亚洲aⅴ乱码一区二区在线播放 | 这个男人来自地球电影免费观看| 欧美日韩精品网址| 欧美成人性av电影在线观看| 国产精品乱码一区二三区的特点| 在线观看美女被高潮喷水网站 | 欧美黑人欧美精品刺激| 欧美另类亚洲清纯唯美| 18禁黄网站禁片免费观看直播| 美女 人体艺术 gogo| 久久久久久人人人人人| 别揉我奶头~嗯~啊~动态视频| 亚洲精品一卡2卡三卡4卡5卡| 国产伦人伦偷精品视频| 一本综合久久免费| 国产精品精品国产色婷婷| 亚洲国产欧美网| 男女床上黄色一级片免费看| 黑人欧美特级aaaaaa片| 黄片小视频在线播放| 精品午夜福利视频在线观看一区| 亚洲成人中文字幕在线播放| 99热这里只有精品一区 | 亚洲片人在线观看| 熟女少妇亚洲综合色aaa.| 神马国产精品三级电影在线观看 | 日韩欧美国产一区二区入口| 黄色片一级片一级黄色片| 亚洲国产高清在线一区二区三| 成人午夜高清在线视频| 在线十欧美十亚洲十日本专区| 亚洲av电影在线进入| 黄色毛片三级朝国网站| 亚洲av电影在线进入| 国产探花在线观看一区二区| 国产av一区二区精品久久| 亚洲一区高清亚洲精品| av中文乱码字幕在线| 国内精品久久久久久久电影| 人人妻人人澡欧美一区二区| 欧美黄色淫秽网站| 午夜影院日韩av| 无人区码免费观看不卡| 99国产极品粉嫩在线观看| 日本撒尿小便嘘嘘汇集6| 欧美一区二区精品小视频在线| 给我免费播放毛片高清在线观看| 精品国产超薄肉色丝袜足j| 亚洲精品久久国产高清桃花| 欧美成人午夜精品| 制服诱惑二区| 麻豆久久精品国产亚洲av| 国产精华一区二区三区| 成人特级黄色片久久久久久久| a在线观看视频网站| 亚洲人成网站在线播放欧美日韩| 又大又爽又粗| 亚洲中文字幕日韩| www.www免费av| 国产精品98久久久久久宅男小说| 99riav亚洲国产免费| 亚洲电影在线观看av| 两性夫妻黄色片| 亚洲中文字幕日韩| 久9热在线精品视频| 12—13女人毛片做爰片一| 一级作爱视频免费观看| 12—13女人毛片做爰片一| 99精品久久久久人妻精品| 老熟妇仑乱视频hdxx| 午夜激情福利司机影院| 亚洲自拍偷在线| 女人被狂操c到高潮| 午夜免费成人在线视频| 国产精品亚洲av一区麻豆| 亚洲美女黄片视频| 美女扒开内裤让男人捅视频| 午夜a级毛片| 国产久久久一区二区三区| 日本 av在线| 成人18禁在线播放| 亚洲av成人av| 在线国产一区二区在线| 久久中文字幕一级| 欧美激情久久久久久爽电影| 最近最新免费中文字幕在线| 亚洲专区国产一区二区| 18禁裸乳无遮挡免费网站照片| av免费在线观看网站| 欧美在线一区亚洲| 亚洲人成网站在线播放欧美日韩| 成人av在线播放网站| 日本免费一区二区三区高清不卡| 久久久久性生活片| 天天躁狠狠躁夜夜躁狠狠躁| 国产激情久久老熟女| 少妇被粗大的猛进出69影院| 九色国产91popny在线| 久久精品国产清高在天天线| 亚洲人成网站高清观看| 国产亚洲欧美在线一区二区| 女人爽到高潮嗷嗷叫在线视频| 久久中文字幕一级| 欧美日韩瑟瑟在线播放| 最近最新免费中文字幕在线| 国产一级毛片七仙女欲春2| av福利片在线| 国产精品影院久久| 女人被狂操c到高潮| 色噜噜av男人的天堂激情| 正在播放国产对白刺激| 国产av不卡久久| 成人精品一区二区免费| 欧美性猛交╳xxx乱大交人| 亚洲国产精品合色在线| 高清毛片免费观看视频网站| 人妻夜夜爽99麻豆av| 久久香蕉激情| 亚洲精品一区av在线观看| 成熟少妇高潮喷水视频| 他把我摸到了高潮在线观看| 免费在线观看日本一区| 国产精品精品国产色婷婷| 999久久久精品免费观看国产| 18美女黄网站色大片免费观看| 久热爱精品视频在线9| 亚洲精品久久国产高清桃花| 亚洲精品中文字幕在线视频| e午夜精品久久久久久久| 欧美在线黄色| 国产又黄又爽又无遮挡在线| 免费高清视频大片| 久久精品国产综合久久久| 亚洲精品中文字幕一二三四区| 婷婷精品国产亚洲av| 1024视频免费在线观看| 身体一侧抽搐| 久久久精品国产亚洲av高清涩受| 天天躁狠狠躁夜夜躁狠狠躁| 国产片内射在线| 亚洲av美国av| 色综合婷婷激情| 香蕉丝袜av| 亚洲欧美日韩东京热| 老鸭窝网址在线观看| 精品不卡国产一区二区三区| 一本一本综合久久| 久久久国产欧美日韩av| 国产精品爽爽va在线观看网站| 又黄又粗又硬又大视频| 久久精品91无色码中文字幕| 成人av一区二区三区在线看| 国产亚洲欧美98| 日本 av在线| 一级毛片女人18水好多| 亚洲性夜色夜夜综合| 亚洲最大成人中文| 日韩高清综合在线| 国产精品综合久久久久久久免费| 国产69精品久久久久777片 | 18美女黄网站色大片免费观看| 麻豆久久精品国产亚洲av| 国产成人一区二区三区免费视频网站| 色在线成人网| 天堂影院成人在线观看| 一个人免费在线观看的高清视频| 激情在线观看视频在线高清| 真人一进一出gif抽搐免费| 国产亚洲精品第一综合不卡| 国产久久久一区二区三区| 88av欧美| 国产亚洲精品一区二区www| cao死你这个sao货| 亚洲一区二区三区色噜噜| 美女 人体艺术 gogo| 精品久久久久久,| 蜜桃久久精品国产亚洲av| 亚洲国产欧洲综合997久久,| 午夜日韩欧美国产| 18禁美女被吸乳视频| 亚洲熟女毛片儿| 午夜激情福利司机影院| 中文字幕人成人乱码亚洲影| 国产aⅴ精品一区二区三区波| 哪里可以看免费的av片| 亚洲最大成人中文| 亚洲成av人片免费观看| 亚洲全国av大片| 首页视频小说图片口味搜索| 精品国产美女av久久久久小说| 日日摸夜夜添夜夜添小说| 香蕉丝袜av| 国产精品免费视频内射| 一进一出抽搐动态| 两个人免费观看高清视频| 国产成人av激情在线播放| 午夜福利免费观看在线| 国语自产精品视频在线第100页| 麻豆国产av国片精品| 欧美日本亚洲视频在线播放| 亚洲精品国产一区二区精华液| 国产精品一及| 欧美日本视频| 在线观看免费日韩欧美大片| 在线观看免费视频日本深夜| 欧美人与性动交α欧美精品济南到| 亚洲欧美日韩无卡精品| 人妻丰满熟妇av一区二区三区| 亚洲av电影在线进入| 久久久久国产精品人妻aⅴ院| 男插女下体视频免费在线播放| 国产野战对白在线观看| 国内久久婷婷六月综合欲色啪| av有码第一页| netflix在线观看网站| 1024视频免费在线观看| 亚洲精品一区av在线观看| 午夜成年电影在线免费观看| 国产av不卡久久| 亚洲欧美日韩东京热| 一级作爱视频免费观看| 少妇人妻一区二区三区视频| 亚洲欧洲精品一区二区精品久久久| 国产一区二区激情短视频| 成人精品一区二区免费| 亚洲精华国产精华精| 午夜福利高清视频| 一卡2卡三卡四卡精品乱码亚洲| 麻豆国产97在线/欧美 | 成在线人永久免费视频| 一二三四在线观看免费中文在| 亚洲成av人片免费观看| 亚洲国产精品999在线| 国产成人av激情在线播放| 国产亚洲精品久久久久5区| 在线观看www视频免费| 欧美中文日本在线观看视频| 少妇被粗大的猛进出69影院| 国产亚洲精品av在线| 中国美女看黄片| av天堂在线播放| www.熟女人妻精品国产| 亚洲国产欧美人成| 亚洲av五月六月丁香网| 国内精品久久久久久久电影| 1024香蕉在线观看| 亚洲午夜理论影院| 黄片大片在线免费观看| 亚洲国产精品sss在线观看| 两个人看的免费小视频| 久久中文字幕人妻熟女| 精品国产超薄肉色丝袜足j| 成熟少妇高潮喷水视频| 国产av不卡久久| 两性午夜刺激爽爽歪歪视频在线观看 | 首页视频小说图片口味搜索| 免费电影在线观看免费观看| 韩国av一区二区三区四区| 久久性视频一级片| 国产不卡一卡二| 亚洲人成网站高清观看| 亚洲精品国产精品久久久不卡| 99国产精品一区二区三区| 久久久久国内视频| 亚洲 国产 在线| 中文字幕最新亚洲高清| 久久人妻福利社区极品人妻图片| 国产精品一区二区三区四区免费观看 | 搡老岳熟女国产| 国产激情欧美一区二区| 我要搜黄色片| 日韩中文字幕欧美一区二区| 精品久久蜜臀av无| 床上黄色一级片| 国产精品亚洲一级av第二区| bbb黄色大片| 99久久精品热视频| 国产亚洲精品一区二区www| tocl精华| 中文字幕人成人乱码亚洲影| 一区二区三区国产精品乱码| 中国美女看黄片| 欧美日本亚洲视频在线播放|